Aligos Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-1.5M | $-23.0M | $-31.5M | $-15.9M | $43.1M | $-19.3M | $5.1M | $-34.9M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $300.0K | $346.0K | $200.0K | $300.0K | $194.0K | $300.0K | $300.0K | $282.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $1.3M | — | — | $959.0K | — | — | $2.6M |
| Net Cash from Operating Activities | $-25.0M | $-23.1M | $-24.3M | $-15.5M | $-20.9M | $-20.1M | $-19.5M | $-22.7M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $34.9M | — | — | $-44.1M | — | — | $-88.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $-62.0K | — | — | $101.7M | — | — | $-19.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |